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Assessment measures in systemic 
lupus erythematosus
Eutília Andrade Medeiros Freire1, Laís Medeiros Souto2, Rozana Mesquita Ciconelli3
ABSTRACT
Systemic lupus erythematosus (SLE) is a chronic inflammatory, multisystem, autoimmune and multifactorial disease, 
whose diagnosis is based on clinical and laboratorial parameters. This study aimed at investigating assessing measures 
in SLE available in the literature by using the method of integrative review of the literature. The bibliographic research 
was conducted through the search for scientific articles indexed in general health sciences databases, such as the Latin 
American and Caribbean Health Sciences (LILACS), MEDLINE/PubMed, and Scientific Electronic Library Online 
(SCIELO). The following descriptors were used: “assessment and lupus”; “quality of life and lupus”; “damage and 
lupus”; “activity index and lupus”; and “patient outcomes and lupus”. The selected publications showed three domains 
of SLE assessment: assessing measures of disease activity; assessing measures of damage caused by the disease; and 
assessing measures of quality of life. The study showed that the patients’ perception of health status and quality of life 
and the impact of the disease and its treatment can be better evaluated using the measures proposed by the authors. 
Keywords: systemic lupus erythematosus, damage assessment, outcome assessment (health care), quality of life.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic inflammatory 
disease of the connective tissue, of multifactorial etiology, 
characterized by affecting several organs and systems and 
being accompanied by important immune disorders. It has auto-
antibodies directed mainly against nuclear antigens, some of 
which participate in immune-mediated tissue injuries. Although 
it can affect both sexes and any age bracket, its incidence is higher 
among women (10:1), with a peak around 30 years of age.1
Despite its unknown etiology, a set of the following 
different factors are believed to trigger SLE: genetic factors, 
supported by the higher prevalence of SLE among first- and 
second-degree relatives; environmental factors, specially 
ultraviolet radiation; viral infections; chemical substances; 
sexual hormones; and emotional factors. The interaction 
among those multiple factors is associated with loss of 
immune regulation, loss of immune tolerance, development of 
autoantibodies, deficient removal of immune complexes, and 
activation of the complement system and other inflammatory 
processes that lead to cell and/or tissue injury.
The clinical manifestations of SLE vary, and can affect any 
organ or system, in isolation or simultaneously, at any phase 
of the disease. Systemic lupus erythematosus affects mainly 
the joints, skin, blood cells, blood vessels, serous membranes, 
kidneys, and brain.
Being a multisystem disease, frequently of insidious onset 
and variable clinical presentation, the diagnosis of SLE can 
be difficult, mainly on an initial assessment. No clinical or 
laboratory alteration in isolation makes the diagnosis of SLE, 
although many of such alterations can be very suggestive of the 
disease. In 1982, the American College of Rheumatology (ACR) 
proposed the criteria for classifying SLE,2 which were reviewed 
in 1997.3 Initially, the criteria elaboration aimed at homogenizing 
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populations for scientific studies. However, because of their 
high sensitivity and specificity, in clinical practice, the criteria 
are often used for diagnosing patients with SLE.
Disease activity is mainly controlled by the use of 
corticosteroids and immunosuppressive drugs, which have 
several side effects, such as arterial hypertension, diabetes, 
osteoporosis, and neoplasias. Thus, identifying and even 
predicting disease activity is paramount for the proper planning 
of disease treatment. Serological tests can be used to assess 
disease activity, the most important being measuring anti-dsDNA 
antibodies, levels of complement and its products, and serum 
levels of interleukins, specially IL-6, IL-10, and IL-16. No 
serological marker correlates with disease activity in all patients.4
The SLE prevalence has increased, as mortality has 
decreased over the years, because of the development of 
new therapeutic options and appearance of more sensitive 
and specific immunological and genetic tests for an earlier 
diagnosis. Currently, the 5-year survival in SLE is estimated to 
range from 97% to 80%.5,6 That increase in survival leads to the 
occurrence of sequelae and disability due to the disease itself 
or its treatment, involving personal care, locomotion, agility, 
behavior, communication, well-being, and other activities.7,8,9
Because the disease is chronic and incurable, the treatment 
is aimed at suppressing disease activity, which is reversible, 
and at preventing the appearance of organ injuries caused by 
the disease, and of side effects secondary to the drugs used, in 
addition to controlling associated comorbidities.10
During the clinical follow-up of a patient with SLE, the 
physician should answer the following questions: has the 
disease improved, worsened, or remained stable?; is the 
presence of irreversible injury due to the disease or to the 
treatment instituted?; what is the patient’s perception about 
his/her health status and quality of life, since it often differs 
from that of the physician?11
Regarding patients who survived longer than 10 years, the 
cause of death almost always does not relate to the SLE activity 
but to chronic injuries caused by the disease or its treatment.12 
For the prognosis of SLE, patients should be assessed for 
disease activity, injuries accumulated during the disease, and 
quality of life.
This study aimed at investigating measures for SLE 
assessment available in the literature.
MATERIAL AND METHODS 
For the present study, the method chosen was the integrative 
review of the literature, which aims at gathering and 
summarizing results of research done on a certain theme or 
question, in a systematic and ordered way, contributing to 
deepen knowledge on the investigated theme.13 That method 
summarizes the already concluded studies and provides 
conclusions from a theme of interest, differing from the 
systematic review. While the systematic review includes only 
experimental studies, the integrative review has a broader 
approach, including experimental and quasi-experimental 
studies, and theoretical and empiric studies. The elaboration 
process of the integrative review follows carefully six stages: 
selection of hypotheses or questions for review; selection of 
the research that will constitute the review sample; definition 
of the characteristics of the primary research constituting the 
review sample; interpretation of the results; and report of the 
review providing a critical exam of the findings.14
The bibliographic survey of this review consisted in 
searching for scientific articles indexed in general health 
sciences databases, such as LILACS (Latin American and 
Caribbean Health Science journals), MEDLINE/PubMed, and 
Scientific Electronic Library Online (SCIELO). The descriptors 
used in the search were as follows: “assessment and lupus”; 
“quality of life and lupus”; “damage and lupus”; “activity index 
and lupus”; and “patient outcomes and lupus”. 
The inclusion criteria used for selecting the sample were 
as follows: full texts available through access to the portal of 
periodicals of the Brazilian Coordination for the Improvement 
of Higher-Level-Education Personnel (CAPES); and 
analysis of the variables considered in the study (assessment 
measures). The most relevant publications were selected 
and their data analyzed and presented in a discursive and 
narrative way.
RESULTS AND DISCUSSION 
Measures for assessing disease activity
Disease activity indices have been created aiming at 
standardizing the SLE activity assessment. Some of such 
indices are as follows: ECLAM (European Consensus Lupus 
Activity Measurement); LAI (Lupus Activity Index); SLAM 
(Systemic Lupus Activity Measure); BILAG (British Isles 
Lupus Assessment Group); and SLEDAI (Systemic Lupus 
Erythematosus Disease Activity Index). The last three 
indices proved to be reproducible and valid, and to have good 
intercorrelation.15
The ECLAM index assesses disease activity over the 
previous month, and comprises 15 clinical and laboratory 
parameters, with scores ranging from 0 to 10.10 Its reliability, 
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validity, and sensitivity to detect changes have been evaluated 
in several studies, and it has a good correlation with other 
indices used.
LAI includes four scores for the physician’s global 
evaluation and his/her opinion regarding disease severity, 
laboratory findings, and immunosuppressive treatment. Its 
mean ranges from 0 to 3. Variations of 0.26 are considered 
alterations for disease activity.10
SLEDAI has been used for assessing disease activity in 
several centers,16 and its validity and reproducibility have 
been evaluated in Brazil.17 It takes into consideration the organ 
affected and includes clinical and laboratory parameters in its 
evaluation. SLEDAI assesses disease activity in the previous 
10 days. Scores greater than 8 indicate active disease. A 
three-point variation between medical visits is considered 
disease activation, and variations greater than or equal to 
12 points mean severe activity.18 In the year 2000, SLEDAI 
was reviewed, originating SLEDAI-2K.19 The modification 
proposed included the persistent activity of some parameters, 
instead of those parameters’ scores only at their beginning or 
relapse. Gladman et al.19 showed that the persistence of rash, 
mucosal ulcers, alopecia, and proteinuria greater than 0.5 g 
in 24h can be used in studies to assess disease activity, when 
comparing SLEDAI-2K and original SLEDAI. Uribe et al.20 
assessed three different instruments used to measure SLE 
activity [modified SLAM, Mexican SLEDAI (Mex-SLEDAI), 
and modified SLEDAI-2K (without the serological parameters: 
anti-dsDNA and serum complement)] and compared them 
with SLEDAI-2K and with the physician’s global evaluation 
of disease activity. Those authors concluded that the three 
instruments correlated well with SLEDAI-2K and with the 
physician’s global evaluation. In addition, the modified 
SLEDAI-2K had the best discriminative validity (ability to 
differentiate clearly active patients from inactive ones or those 
with minimum activity) and the lowest cost among the three 
instruments assessed. 
The BILAG index also measures SLE clinical activity and 
was developed on the principle of the physician’s intention-to-
treat. That index is composed of eight organ-based systems, 
and no total score is calculated. Instead, the BILAG index 
reports disease activity in each of the eight organ-based 
systems separately (general symptoms, mucocutaneous, 
respiratory, cardiovascular, neurological, musculoskeletal, 
renal, and hematological systems), depending on the clinical 
characteristics present and their behavior in the preceding 
four weeks (whether they are new or the same, aggravated 
or improved). It is represented with alphabetical letters. 
BILAG “A” represents the presence of one or more severe 
SLE characteristics. BILAG “B” indicates more moderate 
characteristics of the disease. BILAG “C” includes only mild 
symptomatic characteristics. BILAG “D” represents only the 
previous activity, with no current symptoms caused by active 
lupus. BILAG “E” indicates that a system has never been 
involved. This is an understandable and flexible instrument, 
used as a transitional index of easy and fast application.21,22
Measures for assessing the damage caused by SLE
Instruments for assessing the damage index in organ-based 
systems, detecting damages in patients regardless of their 
cause, which could have resulted from disease activity or 
treatment and also comorbidities, should be used as a health 
measure in patients with chronic diseases. To avoid confusion 
between disease activity and damage, the symptom has to be 
present for at least six months, causing tissue damage, which 
results in irreversible organ damage.
In 1996, ACR published the initial validation of an 
instrument for assessing damage indices in LES, the Systemic 
Lupus International Collaborating Clinics/American College 
of Rheumatology - Damage Index (SLICC/ACR-DI).23 That 
instrument approaches 12 organ-based systems, detecting 
damages in patients regardless of their cause, which can have 
resulted from disease activity or treatment or concomitant 
diseases, such as cancer and diabetes. 
The organ and psychic damages affecting patients who 
survive longer often result in physical or mental disabilities 
and deficiencies, worsening the patients’ quality of life, which 
has been recognized as an important indicator of the health 
status of patients with chronic diseases.24
Measures for assessing quality of life
Health-related quality of life (QoL) scales measure changes 
in physical function, functional, psychological and social 
aspects, and reflect the patient’s perception of his/her health 
status.25 The term QoL began to be used in the USA after the 
Second World War aiming at describing the effect generated 
by the acquisition of material goods (technology) in people’s 
life. It was only some years later that it began to be considered 
an important parameter, aiming at advances in the health and 
education areas. In the medical-social literature, QoL has been 
related to a variety of terms, including life satisfaction, self-
esteem, well-being, happiness, health, life value and meaning, 
functional status, and adjustment.26
According to the WHO, health is defined as the individual’s 
perception about his/her physical, mental, and social well-
being, and not merely the absence of disease or infirmity.27 
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It is a comprehensive concept that comprises physical health, 
psychological status, degree of independence, social relationship, 
beliefs, relationship with the environment, financial gain, and 
freedom. The measures to assess health-related QoL correspond 
to a more limited evaluation of QoL, referring to the dimensions 
specifically and directly related to the health status. That concept 
is often referred to in the medical literature as health-related 
QoL, health status, and functional status.27,28
Although the survival of SLE patients has increased in 
the past 50 years, their QoL remains poor. The measures for 
assessing damages and disease activity consider neither the 
patients’ perspective of the disease nor their QoL.29 Thus, QoL 
assessment is an important parameter for measuring the impact 
of chronic diseases. Physiological measurements provide 
fundamental information for clinicians, but often correlate poorly 
with functional capacity and well-being, aspects patients are 
more interested in and acquainted with. Quality of life should be 
measured as follows: in clinical research, aiming at observing the 
impact of the disease as a complementary qualitative measure; in 
clinical practice evaluation, considering the patient’s perspective 
whenever decisions regarding the disease should be made; 
and in health economic analyses, which study the impact of 
medical actions measured in both quantitative (effectiveness 
and tolerance) and qualitative (QoL) terms, and their relation 
with the expenditure of financial resources.30,31
Most instruments for QoL assessment comprise a number 
of items or questions. The items are grouped into domains or 
dimensions. One domain relates to the behavior or experience 
area being measured. Domains can include questions about 
physical, emotional, and social functions.
The instruments for QoL assessment can be generic or 
specific for a certain disease. The generic instruments can be 
applied to a large variety of diseases and populations, because 
they include aspects relating to function, dysfunction, and 
emotional and physical discomfort, which are relevant to the 
QoL of individuals in general.
The Medical Outcomes Study 36-Item Short-Form Health 
Survey (SF-36) is a generic instrument for QoL assessment, 
easily managed and understood.32 It is a multidimensional 
questionnaire formed by 35 items, grouped into the following 
eight domains: physical functioning; role limitations due to 
physical health; pain; general health perception; vitality; social 
functioning; role limitations due to emotional problems; and 
mental health. It includes one more question about the current 
health perception as compared with that of one year before, 
which is not included in the score calculation. The final score 
ranges from zero to 100, in which zero corresponds to the 
worst general health perception and 100 to the best general 
health perception. Ciconelli et al.33 translated the SF-36 into 
Portuguese and validated it, and the Portuguese version was 
later applied to patients with rheumatoid arthritis, SLE, and 
other rheumatological and non-rheumatological diseases.
Additionally, in assessing the generic health profile, there 
is a preference-based system aimed at measuring health status, 
and that produces a utility score. Assessing health utility 
measures provides information about the patients’ experiences 
with the disease or therapy, the efficacy, effectiveness, and 
efficiency of interventions and health care, and the health status 
of a population in general. The scores of those systems are 
based on the preference for health status in a generic scale that 
ranges from 0.00 (death) to 1.00 (perfect health). That health 
status classification is generic and applicable to all individuals 
in different clinical situations and to the population in general.
Specific instruments assess QoL for a primary area of 
interest. They can be specific for a certain disease, for a certain 
function, or for a problem. Their most important characteristic 
is sensitivity to detect changes after an intervention.
Questionnaires assessing QoL can be self-administered or 
interview-administered. Because of social-economic reasons, 
in studies carried out in Brazil, data have been collected through 
interviews.34,35 
In 2003, the validation of a specific questionnaire for 
SLE, the Systemic Lupus Erythematosus Symptom Checklist 
(SSC) was published, aimed at measuring the impact of the 
disease and its treatment on the individual.36 That questionnaire 
approaches the presence and impact of 38 symptoms related 
to SLE and/or its treatment in a four-point scale, where zero 
is the best health status and four, the worst. 
The internal consistency, reproducibility, and validity have 
been tested in 87 patients with SLE with coefficients of 0.89, 
0.67, and 0.87, respectively, indicating satisfactory correlation 
indices for that questionnaire. Comparison with other QoL 
instruments has shown moderate correlations. Responsiveness 
was tested in 17 patients with lupus nephritis at the beginning 
of treatment with cyclophosphamide and one year after, 
and significant changes were observed in several symptoms 
related to the disease. That questionnaire was translated into 
Portuguese and validated by Freire et al. in 2007.37 
Leong et al.38 have published the development and 
preliminary validation in English of the Systemic Lupus 
Erythematosus Quality of Life Questionnaire (SLEQOL). 
That questionnaire comprises 40 items divided into the 
following six domains: physical functioning; occupational 
activity; symptoms; treatment; mood; and self-image. In 
each domain, the scores vary from 1 to 7, and the higher the 
score, the worse the QoL. The minimum score is 40 and the 
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maximum, 280. It has been tested in 275 patients with SLE, 
the internal consistency (Cronbach coefficient) being 0.95 and 
intraobserver reproducibility, 0.83. Responsiveness was tested 
by using the global health assessment scale, ranging from +7 to 
-7, and the SLEQOL questionnaire underwent several statistical 
treatments that showed it was more sensitive than SF-36 to 
changes over time.38 That questionnaire was also translated 
into Brazilian Portuguese and validated by Freire in 2008.39
New questionnaires have been recently developed and 
published focusing the needs and QoL of SLE patients. 
The Systemic Lupus Erythematosus Needs Questionnaire 
(SLENQ) has seven domains that assess the following 
needs: psychological/spiritual/existential; health services; 
health information; physical; social support; daily living; 
and employment/financial. The questionnaire showed good 
coefficients of reproducibility and moderate correlations with 
SF-36.40
The Lupus Quality of Life (LupusQoL) proved to be a valid 
instrument to assess QoL. It contains 34 items distributed in 
the following eight domains: physical health; emotional health; 
body image; pain; planning; fatigue; intimate relationships; 
and burden to others.41
As health-related QoL scales are part of the assessment 
of patient-reported outcomes (Pros) throughout a disease, 
instruments that measure subjective symptoms and satisfaction 
with treatment also integrate that assessment. Over the past two 
decades, the outcomes of assessment measures centered on the 
patient’s opinion have played an important role in the study 
of chronic diseases. In the ACR, the committee on Outcome 
Measures in Rheumatology Clinical Trials (OMERACT) has 
recognized the importance of measuring functioning and well-
being from the patient’s viewpoint as a criterion to determine 
clinical improvement. In clinical trials, such QoL instruments 
have been largely used as the primary objective, because of 
recommendations to consider the patients’ own assessment 
about their health status, since they are the most interested 
individuals in their own outcome. 
FINAL CONSIDERATIONS
The patient’s perception of his/her health status and QoL, as 
well as of the impact of his/her disease and treatment, has 
been widely recognized as research topics in clinical trials and 
epidemiologic studies. Thus, understanding such measures for 
their use in daily clinical practice is paramount.
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